Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The complexity of producing viable drug candidates is increasing as an abundance of new science keeps extending the range of possible targets and fragmenting disease subtypes. Proximity to novel exploratory research is a driver of pipeline productivity – so can physical location within a communal geography of well-resourced intellectual firepower raise the odds for R&D success? In Vivo sits down with eight key leaders in academia, VC, commercial real estate and groundbreaking biotech to discuss how Los Angeles – the “out there” city of out-sized ambitions – is positioning itself for global leadership in the curative technologies of the future.
Latest From Innovation
In case you missed it: catch up with snippets from interviews published by In Vivo this month.
Castor, a cloud-based data solution, is enabling researchers to effectively capture and integrate data from any source. CEO and founder of the company, Derk Arts, spoke to In Vivo about the importance of cohesive data for the future use of artificial intelligence in biopharma.
Experts from a European data sharing initiative talk to In Vivo about the importance of coordinated computational biology efforts for the future of life sciences innovation and the effective use of artificial intelligence.
Once the stuff of (largely implausible) science fiction, gene therapy is now a clinical reality and one that is taking an increasing share of the pharma R&D limelight. In Vivo takes a look at how these therapies work, how the field has emerged and where it is likely to go next.
Infographic: In Vivo explores trends in personalized medicine, looking at the 25 new molecular entities approved in the US last year with an individualized aspect.
In case you missed it: catch up with snippets from interviews published by In Vivo this week.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.